Trial Profile
Rituximab in Primary Central Nervous system Lymphoma.A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Carmustine; Cytarabine; Methotrexate; Prednisolone; Prednisolone; Teniposide
- Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
- Focus Therapeutic Use
- Acronyms HOVON 105 PCNSL
- 02 Aug 2021 Results assessing the effect of treatment on neurocognitive functioning and the association of neurocognition with radiological abnormalities in primary central nervous system lymphoma published in the Neuro-Oncology
- 01 May 2020 Results assessing impact of rituximab added to standard high-dose methotrexate-based treatment on health-related quality of life, published in the Annals of Oncology
- 07 Jan 2019 Results published in the Lancet Oncology